EE05497B1 - Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha - Google Patents

Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha

Info

Publication number
EE05497B1
EE05497B1 EEP200100472A EEP200100472A EE05497B1 EE 05497 B1 EE05497 B1 EE 05497B1 EE P200100472 A EEP200100472 A EE P200100472A EE P200100472 A EEP200100472 A EE P200100472A EE 05497 B1 EE05497 B1 EE 05497B1
Authority
EE
Estonia
Prior art keywords
polypeptide
cram
polynucleotide
antibody
soluble
Prior art date
Application number
EEP200100472A
Other languages
English (en)
Estonian (et)
Inventor
Albert Imhof Beat
Aurrand-Lions Michel
Original Assignee
Rmf Dictagene S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rmf Dictagene S.A. filed Critical Rmf Dictagene S.A.
Publication of EE200100472A publication Critical patent/EE200100472A/xx
Publication of EE05497B1 publication Critical patent/EE05497B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
EEP200100472A 1999-03-11 2000-03-13 Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha EE05497B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99200746 1999-03-11
PCT/EP2000/002219 WO2000053749A2 (fr) 1999-03-11 2000-03-13 Molecules d'adhesion vasculaire et modulation de leur fonction

Publications (2)

Publication Number Publication Date
EE200100472A EE200100472A (et) 2002-12-16
EE05497B1 true EE05497B1 (et) 2011-12-15

Family

ID=8239973

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100472A EE05497B1 (et) 1999-03-11 2000-03-13 Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha

Country Status (23)

Country Link
US (3) US7393651B2 (fr)
EP (2) EP1163337B1 (fr)
JP (2) JP4836329B2 (fr)
CN (2) CN1637019A (fr)
AT (1) ATE500328T1 (fr)
AU (1) AU782139B2 (fr)
BR (1) BR0008915A (fr)
CA (1) CA2362896C (fr)
CZ (1) CZ303128B6 (fr)
DE (1) DE60045681D1 (fr)
EE (1) EE05497B1 (fr)
ES (1) ES2361905T3 (fr)
HK (1) HK1044169A1 (fr)
HU (1) HU229376B1 (fr)
IL (1) IL145310A0 (fr)
IS (1) IS2819B (fr)
MX (1) MXPA01009110A (fr)
NO (1) NO333085B1 (fr)
NZ (1) NZ514091A (fr)
PL (1) PL207994B1 (fr)
RU (1) RU2244748C2 (fr)
WO (1) WO2000053749A2 (fr)
ZA (1) ZA200107283B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
CN1637019A (zh) * 1999-03-11 2005-07-13 Rmf迪克塔吉恩有限公司 血管粘着分子及其功能的调节
GB0100750D0 (en) * 2001-01-11 2001-02-21 Inpharmatica Ltd Novel proteins
WO2003006673A2 (fr) * 2001-07-11 2003-01-23 Texas Biotechnology Corporation Acide nucleique codant une proteine d'adhesion jonctionnelle humaine (jam3)
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
EP1533617A1 (fr) * 2003-11-19 2005-05-25 RMF Dictagene S.A. Molécules inhibant l'angiogénèse, leur sélection, production et utilisation pour le traitement et diagnose du cancer
KR20150055628A (ko) 2005-11-04 2015-05-21 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
RU2464030C2 (ru) * 2006-05-26 2012-10-20 Регадо Байосайенсиз, Инк. Введение противосвертывающей системы reg1
EP2068928A2 (fr) 2006-09-28 2009-06-17 Merck Serono SA Composés se liant aux molécules d'adhérence jonctionnelles c (jam-c) et procédés d'utilisation correspondants
PL2097455T3 (pl) 2006-11-02 2015-04-30 Genentech Inc Humanizowane przeciwciała przeciw czynnikowi D
FR2909092B1 (fr) * 2006-11-24 2012-10-19 Pf Medicament Nouveaux anticorps anti-proliferation
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
JP5815945B2 (ja) * 2007-08-06 2015-11-17 ノクソン・ファルマ・アクチエンゲゼルシャフト Ｓｄｆ−１結合核酸およびその使用
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
MX2016001854A (es) 2013-08-12 2016-09-06 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento.
TW201623337A (zh) 2014-05-01 2016-07-01 建南德克公司 抗－因子ｄ抗體變異體及其用途
JP2018536650A (ja) 2015-10-30 2018-12-13 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体コンジュゲート及びその使用
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053753A2 (fr) * 1999-03-08 2000-09-14 Genentech, Inc. Activation ou inhibition de l'angiogenese et de la cardiovascularisation
US20030170864A1 (en) * 2000-05-30 2003-09-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
SE9604470D0 (sv) * 1996-12-04 1996-12-04 Tamas Bartfai Konsulting Ab Transmembrane component of tight junction
EP0973892A2 (fr) * 1997-03-14 2000-01-26 Human Genome Sciences, Inc. 28 proteines secretees par l'homme
AU6578398A (en) * 1997-03-21 1998-10-20 Genetics Institute Inc. Secreted proteins and polynucleotides encoding them
EP1000149B1 (fr) 1997-08-01 2007-05-09 Serono Genetics Institute S.A. Est 5' pour proteines secretees identifiees dans le tissu cerebral
US20030077654A1 (en) * 1997-09-17 2003-04-24 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1002864A1 (fr) * 1998-11-10 2000-05-24 Universita' degli studi di Bologna HIgR et domaine V relié pour la préparation d'un médicament pour la prévention et le traitement des infections de HSV-1, HSV-2 et BHV
MXPA01006057A (es) * 1998-12-16 2003-09-10 Genentech Inc Polipeptidos secretados y transmembranales y acidos nucleicos que los codifican.
CN1637019A (zh) * 1999-03-11 2005-07-13 Rmf迪克塔吉恩有限公司 血管粘着分子及其功能的调节
EP1533617A1 (fr) * 2003-11-19 2005-05-25 RMF Dictagene S.A. Molécules inhibant l'angiogénèse, leur sélection, production et utilisation pour le traitement et diagnose du cancer
US7642341B2 (en) * 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer

Also Published As

Publication number Publication date
EE200100472A (et) 2002-12-16
AU4105100A (en) 2000-09-28
EP2292761A1 (fr) 2011-03-09
US7670826B2 (en) 2010-03-02
HUP0200606A3 (en) 2004-11-29
PL350417A1 (en) 2002-12-16
ES2361905T3 (es) 2011-06-24
JP4836329B2 (ja) 2011-12-14
US8143056B2 (en) 2012-03-27
CN1355843A (zh) 2002-06-26
IL145310A0 (en) 2003-01-12
WO2000053749A2 (fr) 2000-09-14
NO20014417L (no) 2001-11-12
ATE500328T1 (de) 2011-03-15
US20080274970A1 (en) 2008-11-06
PL207994B1 (pl) 2011-02-28
NO20014417D0 (no) 2001-09-11
ZA200107283B (en) 2002-12-24
IS6072A (is) 2001-09-10
MXPA01009110A (es) 2002-08-20
CA2362896A1 (fr) 2000-09-14
WO2000053749A3 (fr) 2000-12-14
CN1637019A (zh) 2005-07-13
US7393651B2 (en) 2008-07-01
US20050266426A1 (en) 2005-12-01
HUP0200606A2 (en) 2002-06-29
IS2819B (is) 2012-12-15
CZ20013267A3 (cs) 2002-02-13
JP2002537837A (ja) 2002-11-12
EP1163337A2 (fr) 2001-12-19
JP2010233572A (ja) 2010-10-21
AU782139B2 (en) 2005-07-07
CA2362896C (fr) 2012-07-31
NZ514091A (en) 2004-01-30
CN100469878C (zh) 2009-03-18
RU2244748C2 (ru) 2005-01-20
EP1163337B1 (fr) 2011-03-02
CZ303128B6 (cs) 2012-04-18
US20100267649A1 (en) 2010-10-21
HU229376B1 (en) 2013-11-28
BR0008915A (pt) 2002-04-09
HK1044169A1 (en) 2002-10-11
NO333085B1 (no) 2013-02-25
DE60045681D1 (de) 2011-04-14

Similar Documents

Publication Publication Date Title
EE05497B1 (et) Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
DE69333348D1 (de) Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv-verwandten krankheiten
TR200202254T2 (tr) IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri.
ATE431359T1 (de) Copolymer-1-verwandte polypeptide für die verwendung als molekulargewichtsmarker und zur therapie
DE68929043T2 (de) Für androgen-rezeptor-protein kodierende dna
DE59101889D1 (de) Variante cd44-oberflächenproteine, diese kodierende dna-sequenzen, antikörper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie.
DE68925226D1 (de) Monoklonale Antikörper
KR980002066A (ko) 변이형 인간 성장호르몬 및 그의 용도
DE69737651D1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
DE69529272T2 (de) MONOKLONALER ANTIKÖRPER GEGEN DAS HUMANE Mx-PROTEIN MxA
NO993653L (no) FremgangsmÕte for diagnose, prognose og behandling av glaukom og relaterte sykdommer
ATE301194T1 (de) Beta-defensine
ES2061566T3 (es) Anticuerpos monoclonales contra la proteina e7 del papilomavirus humano tipo 16, procedimiento para su preparacion, asi como su empleo.
TR200000416T2 (tr) Neisseria loctoferrin bağlayıcı protein.
DK1431391T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
DK0870036T3 (da) Syntetisk pattedyrs-alfa-N-acetylglucosaminidase og genetiske sekvenser kodende derfor
BR0007816A (pt) Fator de estimulação óssea
NO940797L (no) Reseptorderivater som har bindingseter for human-rhinovirus

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
HE1A Change of address
MM4A Lapsed by not paying the annual fees

Effective date: 20180313